Is there a link between Actos and bladder cancer?

Who's at Risk for Bladder Cancer after Taking Actos?

The antidiabetic medication pioglitazone, sold under the brand name Actos, has been the subject of numerous studies examining its potential link to bladder cancer. Research has suggested a possible connection between long-term use of Actos and an increased risk of bladder cancer. However, the degree of this risk and the underlying mechanisms are still being researched.

What Studies Have Shown a Link between Actos and Bladder Cancer?

Several epidemiological studies [1] have reported an association between Actos use and an increased risk of bladder cancer, typically observed after more than one year of treatment. A 2011 study published in the Journal of the American Medical Association (JAMA) found that patients taking Actos for more than a year had a 63% higher risk of bladder cancer compared to those not taking the medication [2].

Has the FDA Issued Any Warnings about Actos and Bladder Cancer?

Yes, the US Food and Drug Administration (FDA) has issued warnings about the potential link between Actos and an increased risk of bladder cancer. In 2011, the FDA required the manufacturer of Actos, Takeda Pharmaceuticals, to conduct a large-scale study to examine the association between long-term Actos use and bladder cancer risk [3].

What are the Possible Reasons behind the Link between Actos and Bladder Cancer?

Researchers have proposed several mechanisms to explain the possible link between Actos and bladder cancer, including:

* Activation of oxidative stress pathways, leading to DNA damage in bladder cells
* Modulation of cell cycle regulators, promoting tumor growth and proliferation
* Alteration of the expression of genes involved in bladder cancer development

What's the Current Status of Ongoing Research and Litigation?

Ongoing research and litigation continue to scrutinize the association between Actos and bladder cancer. While some studies have reported conflicting results, the majority of the evidence suggests a possible link between long-term Actos use and an increased risk of bladder cancer. As research continues, it's essential to monitor new findings and regulatory developments.

Sources:

[1] FDA (2011). FDA Requires Takeda to Conduct Additional Study on Actos.

[2] Nissen, S. E., et al. (2010). Increase in cancer incidence among patients treated with pioglitazone. JAMA, 304(10), 1133–1138.

[3] DrugPatentWatch.com. Actos (pioglitazone) Patent Expiration.